Payment overview · 2025
General Payments
$569.85
28 reported records · 11 companies
Healthcare provider profile · identity verified
Mark C Houston, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · NASHVILLE, TN · NPI 1790723013
Verified facts
What the public records show
CMS Open Payments records show Mark C Houston, M.D. received $569.85 in general payments during 2025 across 28 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 24.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Edarbi, Jardiance, Kerendia, Mounjaro, Ozempic, Rybelsus, Synthroid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Synthroid by this doctor in 2024.
Azurity Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EDARBI as an associated drug or biological on 1140 records involving 805 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Edarbi by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $139.13 | 24.4% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $86.06 | 15.1% | 4 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $76.08 | 13.3% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $67.93 | 11.9% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $54.47 | 9.6% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $33.29 | 5.8% | 2 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $31.30 | 5.5% | 1 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $23.75 | 4.2% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.40 | 3.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.30 | 3.2% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $17.14 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $569.85 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $139.13 | 6 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $76.08 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $67.93 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $67.93 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $56.88 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $54.47 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $54.47 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $33.29 | 2 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $31.30 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $29.18 | 1 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $23.75 | 1 | 2025 |
Source payment records
|
|||||
| EDARBI Normalized: edarbi |
Drug | Azurity Pharmaceuticals, Inc. | $22.40 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.30 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $18.30 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $17.14 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $13.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| EDARBI edarbi |
2025 | Edarbi | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 36 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 100 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 52 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 120 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 111 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 49 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
111 | 31 |
| Azurity Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | EDARBI open payments reported associated product |
CMS Open Payments — General Payments 1140 supporting records · 805 recipient NPIs · example record 1242666830 |
Edarbi · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
100 | 22 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
49 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
36 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
120 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Indapamide | Indapamide | 654 | 196 |
| Amlodipine Besylate | Amlodipine Besylate | 636 | 176 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 619 | 188 |
| Telmisartan | Telmisartan | 577 | 164 |
| Levothyroxine Sodium | Levothyroxine Sodium | 407 | 116 |
| Atorvastatin Calcium | Atorvastatin Calcium | 260 | 77 |
| Metformin Hcl | Metformin Hcl | 224 | 67 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 213 | 55 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 212 | 61 |
| Spironolactone | Spironolactone | 195 | 59 |
| Meloxicam | Meloxicam | 169 | 65 |
| Allopurinol | Allopurinol | 134 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 133 | 75 |
| Amiloride Hcl | Amiloride Hcl | 127 | 32 |
| Ozempic | Semaglutide | 120 | 19 |
| Metformin Hcl Er | Metformin Hcl | 119 | 33 |
| Carvedilol | Carvedilol | 117 | 37 |
| Synthroid | Levothyroxine Sodium | 111 | 31 |
| Omeprazole | Omeprazole | 110 | 36 |
| Kerendia | Finerenone | 100 | 22 |
| Repatha Sureclick | Evolocumab | 100 | 18 |
| Prednisone | Prednisone | 97 | 78 |
| Ezetimibe | Ezetimibe | 96 | 33 |
| Nebivolol Hcl | Nebivolol Hcl | 95 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 93 | 29 |
| Farxiga | Dapagliflozin Propanediol | 90 | 27 |
| Simvastatin | Simvastatin | 87 | 25 |
| Pantoprazole Sodium | Pantoprazole Sodium | 86 | 28 |
| Azithromycin | Azithromycin | 80 | 61 |
| Famotidine | Famotidine | 78 | 28 |
| Losartan Potassium | Losartan Potassium | 76 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 70 | 26 |
| Eliquis | Apixaban | 68 | 19 |
| Lorazepam | Lorazepam | 66 | 21 |
| Torsemide | Torsemide | 62 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 61 | 18 |
| Ramipril | Ramipril | 57 | 16 |
| Mounjaro | Tirzepatide | 52 | suppressed |
| Potassium Chloride | Potassium Chloride | 52 | 15 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 49 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 49 | 17 |
| Montelukast Sodium | Montelukast Sodium | 48 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 47 | 11 |
| Nifedipine Er | Nifedipine | 46 | 11 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 43 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 43 | 17 |
| Januvia | Sitagliptin Phosphate | 42 | 12 |
| Sertraline Hcl | Sertraline Hcl | 39 | 15 |
| Irbesartan | Irbesartan | 37 | 11 |
| Jardiance | Empagliflozin | 36 | 11 |
| Azelastine Hcl | Azelastine Hcl | 33 | 16 |
| Dutasteride | Dutasteride | 32 | suppressed |
| Lisinopril | Lisinopril | 32 | suppressed |
| Gabapentin | Gabapentin | 31 | 12 |
| Rybelsus | Semaglutide | 31 | suppressed |
| Verapamil Er | Verapamil Hcl | 31 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 29 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 29 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 28 | suppressed |
| Alprazolam | Alprazolam | 27 | suppressed |
| Clonazepam | Clonazepam | 27 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 26 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | suppressed |
| Furosemide | Furosemide | 25 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 23 | suppressed |
| Edarbi | Azilsartan Medoxomil | 20 | suppressed |
| Perindopril Erbumine | Perindopril Erbumine | 20 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 17 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Armour Thyroid | Thyroid,pork | 15 | suppressed |
| Clonidine | Clonidine | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 15 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Cabergoline | Cabergoline | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Atenolol | Atenolol | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Saxagliptin Hcl | Saxagliptin Hcl | 11 | suppressed |
| Ursodiol | Ursodiol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $569.85 · 28 records | Bayer Healthcare Pharmaceuticals Inc. | ACCRUFER, AREXVY, EDARBI, FFRct, JARDIANCE, JOURNAVX, Kerendia, Korlym, MOUNJARO, OTEZLA, Ozempic, REPATHA, Rybelsus, SYNTHROID, TRELEGY ELLIPTA, UBRELVY | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Edarbi play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error